Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs

Xenobiotica

Volumn 37, Issue 5, 2007, Pages 503-513

  Ishizuka, M ^a   Nagai, S ^a   Sakamoto, K Q ^a   Fujita, S ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

CYP3A12 and imatinib metabolism; Imatinib pharmacokinetics; Species differences

Indexed keywords

CYTOCHROME P450 2C; CYTOCHROME P450 2C21; CYTOCHROME P450 3A; CYTOCHROME P450 3A12; IMATINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG INTERACTIONS; FEMALE; HAPLORHINI; HUMANS; KETOCONAZOLE; MALE; MICROSOMES, LIVER; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RATS; TIME FACTORS;

CANIS FAMILIARIS; RATTUS;

EID: 34249288362     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600962849     Document Type: Article

References (27)

1. Blaisdell J, Goldstein JA, Bai SA. 1998. Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metabolism and Disposition 26:278-283.
2. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, et al. 2002. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clinical Cancer Research 8:935-942.
3. Downing S, Chien MB, Kass PH, Moore PE, London CA. 2002. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. American Journal of Veterinary Research 63:1718-1723.
4. Graham MJ, Bell AR, Crewe HK, Walker L, Whittaker EF, Lennard MS. 2003. mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica 33:225-237.
5. Graham RA, Downey A, Mudra D, Carroll K, Chengelis C, Madan A, Parkinson A. 2002. In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metabolism and Disposition 30:1206-1213.
6. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben-Am M, et al. 2005. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metabolism and Disposition 33:1503-1512.
7. Ivanovic D, Medenica M, Jancic B, Malenovic A. 2004. Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 800:253-258.
8. Kirkness EF, Bafna V, Halpern AL, Levy S, Remington K, Rusch DB, Delcher AL, Pop M, Wang W, Fraser CM, et al. 2003. The dog genome: Survey sequencing and comparative analysis. Science 301:1898-1903.
9. Kretz O, Weiss HM, Schumacher MM, Gross G. 2004. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. British Journal of Clinical Pharmacology 58:212-216.
10. Kuroha M, Kuze Y, Shimoda M, Kokue E. 2002a. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. American Journal of Veterinary Research 63:900-905.
11. Kuroha M, Azumano A, Kuze Y, Shimoda M, Kokue E. 2002b. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metabolism and Disposition 30:63-68.
12. Kuroha M, Kayaba H, Kishimoto S, Khalil WF, Shimoda M, Kokue E. 2002c. Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. Journal of Pharmaceutical Sciences 91:868-873.
13. Le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, Baskaynak G, Dorken B, Ehninger G, Ottmann O, Jenke A, et al. 2004. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemotherapy and Pharmacology 53:313-323.
14. Litzow MR. 2006. Imatinib resistance: Obstacles and opportunities. Archives of Pathology and Laboratory Medicine 130:669-679.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein Measurement with the Folin phenol Reagent. The Journal of Biological Chemistry 193:265-275.
16. Lu P, Singh SB, Carr BA, Fang Y, Xiang CD, Rushmore TH, Rodrigues AD, Shou M. 2005. Selective inhibition of dog hepatic CYP2B11 and CYP3A12. Journal of Pharmacology and Experimental Therapeutics 313:518-528.
17. Madhusudan S, Ganesan TS. 2004. Tyrosine kinase inhibitors in cancer therapy. Clinical Biochemistry 37:618-635.
18. Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM. 2004. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clinical Cancer Research 10:2525-2529.
19. O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C, Mehring G, Milosavljev S, Huber C, Capdeville R, et al. 2003. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British Journal of Cancer 89:1855-1859.
20. Ohno R. 2006. Treatment of chronic myeloid leukemia with imatinib mesylate. International Journal of Clinical Oncology 11:176-183.
21. Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry 239:2370-2378.
22. Peng B, Lloyd P, Schran H. 2005. Clinical pharmacokinetics of imatinib. Clinical Pharmacokinetics 44:879-894.
23. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. 2004. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. Journal of Clinical Pharmacology 44:158-162.
24. Tasaki T, Nakamura A, Itoh S, Ohashi K, Yamamoto Y, Masuda M, Iwata H, Kazusaka A, Kamataki T, Fujita S. 1998. Expression and characterization of dog CYP2D15 using baculovirus expression system. Journal of Biochemistry 123:162-168.
25. Widmer N, Beguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J, Decosterd LA. 2004. Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography- ultraviolet absorbance detection. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 803:285-292.
26. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. 2002. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Veterinary Pathology 39:529-535.
27. Zhao XJ, Ishizaki T. 1997. The in vitro hepatic metabolism of quinine in mice, rats and dogs: Comparison with human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 283:1168-1176.